SEONGNAM, South Korea, Aug. 5, 2024
/PRNewswire/ -- SK pharmteco, a global contract development,
manufacturing, and analytical testing organization serving both the
small molecule and cell & gene therapy industry, and Rznomics
Inc., a South Korea-based
biopharmaceutical company specializing in the development of
RNA-based gene therapeutics, have signed a memorandum of
understanding (MOU) for a contract development and manufacturing
partnership.
When finalized, the multi-year partnership will establish a
strategic collaboration between SK pharmteco and Rznomics to
develop and commercialize multiple gene therapy products. SK
pharmteco will provide technical expertise and resources, including
the facilities and personnel, to enable a smooth transition from
clinical to full-scale commercial manufacturing of Rznomics'
innovative ribonucleic acid (RNA)-based biopharmaceuticals.
"We are thrilled about the opportunity to partner with Rznomics
on their groundbreaking initiatives," said Andy Fenny, Chief Commercial Officer of SK
pharmteco. "By combining our significant expertise in gene therapy
manufacturing with Rznomics' innovative RNA-based therapeutic
approach, we believe this collaboration has the potential to
deliver life-changing treatments to patients in need quickly."
Seong-Wook Lee, President and Chief Executive Officer of
Rznomics, commented: "This partnership will mark late-stage
development and manufacturing of our gene therapy pipeline to
prepare the path towards Phase II and later stage clinical trials
and potential commercialization. We look forward to working closely
with SK pharmteco."
About SK pharmteco
SK pharmteco is a global contract development and manufacturing
organization (CDMO) with 13 offices and manufacturing facilities
across the U.S., Europe, and
Korea. The company partners with biopharmaceutical companies of all
sizes to manufacture Active Pharmaceutical Ingredients (API) and
intermediates, cell and gene therapy technologies, registered
starting materials, and analytical services for the
biopharmaceutical industry worldwide. SK pharmteco is a subsidiary
of SK Inc. (KRX: 034730) (SK), the strategic investment company for
SK Group, South Korea's
second-largest conglomerate.
About Rznomics
Rznomics is a South Korea-based
innovative RNA biopharmaceutical company, with vision to
treat/conquer various human intractable diseases.
Rznomics has developed and focused on several pipelines with RNA
editing platform technologies of RZ-001 (Hepatocellular Carcinoma,
Glioblastoma), RZ-003 (Alzheimer), RZ-004 (Retinitis Pigmentosa),
RZ-005 (neurodegenerative disorder) and Circular RNA platform.
For RZ-001, the lead pipeline, Rznomics has received Phase I/IIa
IND approvals from the FDA for Hepatocellular Carcinoma and
Glioblastoma in 2022 and 2023 each. In addition, FDA has granted
Fast Track Designation for GBM in November
2023 and Orphan Drug Designation for HCC in January 2024.
Early-phase trials have also commenced in Korea, upon IND
approval for RZ-001 from the Ministry of Food and Drug Safety
(MFDS). Rznomics has received IND approval for combination of
RZ-001 and Immunotherapy from the MFDS as well, in December 2023.
Contact:
Keith Bowermaster, APR, CCMP
Communications Consultant
keith.bowermaster@skpt.com
Website: www.skpharmteco.com
Jihye Yang
Associate Manager
jhyang@rznomics.com
Website: www.rznomics.com
View original
content:https://www.prnewswire.com/news-releases/sk-pharmteco-and-rznomics-explore-collaboration-for-rna-based-gene-therapy-development-and-manufacturing-302213313.html
SOURCE Rznomics Inc.